Paradigm Biopharma
Presence
Paradigm Biopharma is a company listed under the stock ticker PAR (AU).
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Paradigm Biopharma
- Paul Rennie, Chief Executive Officer and Chairman of the Board
- Amos Meltzer, Non-Executive Director
- Helen Fisher, Non-Executive Director
Popular executive movements at Paradigm Biopharma
- John Gaffney, Non-Executive Director, has left the company (posted on October 22 2023).
Create your alert
to follow the executive moves at Paradigm Biopharma.
Biotechnology
Paradigm Biopharma has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Paradigm Biopharma
- The arthritic Paradigm
- Paradigm receives ethics approval for osteoarthritis trial
- Paradigm PPS treatment reduces pain - 9Finance
- Ground-breaking new treatment set to ease arthritis pain
Social media about Paradigm Biopharma
- Paradigm Biopharma on Wikipedia, Google News & Yahoo Finance
- Paradigm Biopharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Paul Rennie 
Call Paradigm Biopharma at +61 39...
